All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
A multi-institutional team of researchers has reported the development of an anti-IL-8 antibody against endometriosis using recycling antibody engineering technology. The study confirmed the role of the inflammatory cytokine IL-8 in the development of inflammation and fibrosis in endometriosis and showed that administration of IL-8 antibodies in primate models improved endometriosis pathology.
Researchers from Revolo Biotherapeutics Ltd. have presented preclinical data for IRL-201104, a clinical-stage immunomodulatory peptide that has previously demonstrated a long-lasting effect in different preclinical models of allergic inflammation. In the new studies, the candidate was assessed in models of food allergy.
Aldeyra Therapeutics Inc. is eyeing the start of clinical trials with reactive aldehyde species (RASP) modulators ADX-246 for systemic immune-mediated diseases and ADX-248 for geographic atrophy.
Antibodies against tumor necrosis factor (TNF) and IL-6 receptor are the most effective available therapies against rheumatoid arthritis (RA). However, no cure for RA exists. In work published in Science Translational Medicine, scientists from Sanofi R&D (Sanofi SA) investigated whether dual inhibition of TNF and IL-6 could improve the therapeutic efficacy against RA.
An international team of researchers has created two bat stem cell lines that reveal an unusual number of viral sequences in bat cells compared with those of other mammals. Writing in an article posted online Feb. 21, 2023, in Cell, the scientists suggested that the unusual amount of viral genetic material found in the bat stem cells could explain why these mammals are largely unaffected by most viral infections, despite being able to transmit them.
When oxygen levels of the intestine increase, the appropriate hypoxic conditions for intestinal microbiota are lost. This state may be caused by immune-mediated malfunction of the intestinal epithelium. By controlling oxygen levels, the imbalance in the intestinal microbiome (dysbiosis) can be reduced.
Coya Therapeutics Inc. has announced expansion of its exclusive worldwide rights for the development and commercialization of COYA-301, the company's low-dose IL-2 subcutaneous administration product candidate. COYA-301 is intended to enhance regulatory T-cell (Treg) function in vivo to treat the systemic neuro-inflammation underlying certain autoimmune and neurodegenerative diseases.
Boston Immune Technologies and Therapeutics Inc. (BITT) has announced progress using its Domab platform. Two Domab CD40 antagonists, BITT-CD4D11 and BITT-CD4F10, have completed discovery and optimization and a final candidate is being selected for IND-enabling steps.
Researchers from The Salk Institute have described a signaling pathway that sets off an unusual, autophagy-dependent cell death mechanism as a fail-safe for cells that have evaded senescence mechanisms. The scientists found a tumor suppression mechanism mediated by telomere signaling, which activated an innate immune response through mitochondrial and telomere complexes to eliminate cells with shortened telomeres.
RSS
